海普瑞(09989.HK) 公布，于本周二(12月31日)与永太药业签订分销协议，据此，永太药业授予公司在美国全境商业化加巴喷丁胶囊Gabapentin的许可。根据协议，公司将向永太药业以约定价格购买标的药品，并将负责标的药品在美国市场的商业化工作。除协议明确约定的标的药品供货价格以外，公司无需另行向永太药业支付任何款项。加巴喷丁是一种常用的抗癫痫药物，被广泛用于治疗神经痛和其他疼痛性疾病。(ha/da)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.